Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Clin Cancer Res. 2022 Sep 1;28(17):3752–3760. doi: 10.1158/1078-0432.CCR-22-0741

Figure 1.

Figure 1.

A) Flow diagram of patient plasma availability and EGFR mutation positivity in ctDNA. Time course showing treatment-induced changes in EGFR MAF for B) all patients with a positive BL EGFR MAF and a C3D1 timepoint (n = 62), and C) for all patients with both C3D1 and PRG timepoints (right side, n = 46). Red lines indicate cases with residual ctDNA at C3D1; blue lines indicate cases with complete clearance at C3D1. The graph is log-transformed to highlight differences at low MAFs.